Treatment of Autoimmune Enteropathy With Vedolizumab

Autoimmune enteropathy (AIE) is a rare condition characterized by immune-mediated villous atrophy with associated chronic diarrhea. In this case, a 34-year-old man with AIE was treated with vedolizumab, an anti-ɑ4b7 integrin that inhibits intestinal lymphocyte trafficking, after initial treatments with prednisone, open-capsule budesonide, azathioprine, infliximab, and adalimumab showed minimal response. Vedolizumab resulted in moderate symptomatic and histological improvement but was discontinued due to possible drug-induced liver injury. This case suggests the potential therapeutic efficacy of vedolizumab in treating AIE, though more research is needed.